Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

NCT05870761 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Endometrial Serous Adenocarcinoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
BIOLOGICAL: Dostarlimab
PROCEDURE: Magnetic Resonance Imaging
DRUG: Niraparib

Sponsor

Casey Cosgrove